(1) A substance shall be added to schedule I by the
general assembly when:
(a) The substance has high potential for abuse;
(b) The substance has no currently accepted medical use in treatment in the
United States; and
(c) The substance lacks accepted safety for use under medical supervision.
(2) Unless specifically excepted by Colorado or federal law or Colorado or
federal regulation or more specifically included in another schedule, the following
controlled substances are listed in schedule I:
(a) Any of the following synthetic opiates, including any isomers, esters,
ethers, salts, and salts of isomers, esters, and ethers of them that are theoretically
possible within the specific chemical designation:
(I) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl ]
-N- phenylacetamide);
(II) Acetylmethadol;
(III) Allylprodine;
(IV) Alphacetylmethadol;
(V) Alphameprodine;
(VI) Alphamethadol;
(VII) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)- 4-(N-propanilido) piperidine);
(VIII) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-4-piperidinyl]-N-phenylpropanamide);
(IX) Benzethidine;
(X) Betacetylmethadol;
(XI) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-phenylpropanamide);
(XII) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl-] N-phenylpropanamide);
(XIII) Betameprodine;
(XIV) Betamethadol;
(XV) Betaprodine;
(XVI) Clonitazene;
(XVII) Dextromoramide;
(XVIII) Diampromide;
(XIX) Diethylthiambutene;
(XX) Difenoxin;
(XXI) Dimenoxadol;
(XXII) Dimepheptanol;
(XXIII) Dimethylthiambutene;
(XXIV) Dioxaphetyl butyrate;
(XXV) Dipipanone;
(XXVI) Ethylmethylthiambutene;
(XXVII) Etonitazene;
(XXVIII) Etoxeridine;
(XXIX) Furethidine;
(XXX) Hydroxypethidine;
(XXXI) Ketobemidone;
(XXXII) Levomoramide;
(XXXIII) Levophenacylmorphan;
(XXXIV) 3-methylfentanyl (N-[3-methyl-1-(2- phenylethyl)-4-piperidyl]-N-phenylpropanamide);
(XXXV) 3-methylthiofentanyl (N-[3-methyl-1-(2- thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(XXXVI) Morpheridine;
(XXXVII) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(XXXVIII) Noracymethadol;
(XXXIX) Norlevorphanol;
(XL) Normethadone;
(XLI) Norpipanone;
(XLII) Para-fluorofentanyl (N-(4-fluorophenyl)-N- [1-(2-phenethyl) -4-piperidinyl]-propanamide);
(XLIII) PEPAP (1-(-2-phenethyl)-4-phenyl- 4-acetoxypiperidine);
(XLIV) Phenadoxone;
(XLV) Phenampromide;
(XLVI) Phenomorphan;
(XLVII) Phenoperidine;
(XLVIII) Piritramide;
(XLIX) Proheptazine;
(L) Properidine;
(LI) Propiram;
(LII) Racemoramide;
(LIII) Thiofentanyl (N-phenyl-N-[1-(2- thienyl) ethyl-4-piperidinyl]-propanamide);
(LIV) Tilidine;
(LV) Trimeperidine.
(b) Any of the following opium derivatives, including their salts, isomers, and
salts of isomers of them that are theoretically possible within the specific chemical
designation:
(I) Acetorphine;
(II) Acetyldihydrocodeine;
(III) Benzylmorphine;
(IV) Codeine methylbromide;
(V) Codeine-N-Oxide;
(VI) Cyprenorphine;
(VII) Desomorphine;
(VIII) Dihydromorphine;
(IX) Drotebanol;
(X) Etorphine, except hydrochloride salt;
(XI) Heroin;
(XII) Hydromorphinol;
(XIII) Methyldesorphine;
(XIV) Methyldihydromorphine;
(XV) Morphine methylbromide;
(XVI) Morphine methylsulfonate;
(XVII) Morphine-N-Oxide;
(XVIII) Myrophine;
(XIX) Nicocodeine;
(XX) Nicomorphine;
(XXI) Normorphine;
(XXII) Pholcodine;
(XXIII) Thebacon.
(c) Any material, compound, mixture, or preparation containing any quantity
of the following hallucinogenic substances, including any salts, isomers, and salts
of isomers of them that are theoretically possible within the specific chemical
designation:
(I) 4-bromo-2, 5-dimethoxy-amphetamine (Some trade or other names: 4-bromo-2, 5-dimethoxy-alpha- methylphenethylamine; 4-bromo-2, 5-DMA.);
(II) 2,5-dimethoxyamphetamine (Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.);
(II.5) 2,5-Dimethoxy-4-ethylamphetamine (DOET);
(III) 4-methoxyamphetamine (Some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine, PMA.);
(IV) 5-methoxy-3,4-methylenedioxy amphetamine;
(IV.5) 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT);
(V) 4-methyl-2,5-dimethoxy-amphetamine (Some trade and other names: 4-methyl-2,5-dimethoxy-alpha- methylphenethylamine; DOM; and STP.);
(VI) 3,4-methylenedioxy amphetamine;
(VII) 3,4-methylenedioxymethamphetamine (MDMA); except that 3,4-methylenedioxymethamphetamine (MDMA) does not include a prescription drug
product containing 3,4-methylenedioxymethamphetamine (MDMA) approved by the
federal food and drug administration and placed on a schedule of the federal
Controlled Substances Act, 21 U.S.C. sec. 801 et seq., as amended, other than
schedule I, or has been exempted from one or more provisions of such act, and that
is intended for prescribed use and dispensed by a pharmacy or prescription drug
outlet registered by the state of Colorado and only possessed by a person
authorized to possess a controlled substance pursuant to section 18-18-302. Any
such drug product containing MDMA that is approved by the federal food and drug
administration must be controlled in Colorado in the same manner as required by
any federal control designation pursuant to the federal Controlled Substances
Act, or any exemption from one or more provisions of that act, and subject to the
provisions set forth in part 1 of article 280 of title 12 and part 3 of this article 18.
Nothing in this section exempts a person from any violation of part 4 of this article
18.
(VIII) 3,4,5-trimethoxy amphetamine;
(VIII.5) Alpha-methyltryptamine (AMT);
(IX) Bufotenine (Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2- dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.);
(X) Diethyltryptamine (Some trade or other names: N,N-Diethyltryptamine;
DET.);
(XI) Dimethyltryptamine (Some trade or other names: DMT.);
(XII) Ibogaine (Some trade and other names: (7-Ethyl-6,6B,7,8,9,10,12,13-octahydro-2- methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepine [5,4- b] indole;
Tabernanthe iboga.);
(XIII) Lysergic acid diethylamide;
(XIV) Mescaline;
(XV) Parahexyl (Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.);
(XVI) Peyote (Meaning all parts of the plant classified botanically as
Lophophora williamsii Lemaire, whether growing or not, its seeds, any extract from
any part of the plant, and every compound, salt, derivative, mixture, or preparation
of the plant, or its seeds or extracts);
(XVII) N-ethyl MDA;
(XVIII) N-ethyl-3-piperidyl benzilate;
(XIX) N-hydroxy MDA;
(XX) N-methyl-3-piperidyl benzilate;
(XXI) Psilocybin; except that psilocybin does not include a prescription drug
product containing crystalline polymorph psilocybin approved by the federal food
and drug administration and placed on a schedule of the federal Controlled
Substances Act, 21 U.S.C. sec. 801 et seq., other than schedule I, or exempt from
one or more provisions of that act, and that is intended for prescribed use and
dispensed by a pharmacy or prescription drug outlet registered by the state of
Colorado and only possessed by a person authorized to possess a controlled
substance pursuant to section 18-18-302. Any prescription drug product containing
crystalline polymorph psilocybin that is approved by the federal food and drug
administration must be controlled in Colorado in the same manner as required by
any federal control designation pursuant to the federal Controlled Substances
Act, or any exemption from one or more provisions of that act; and is subject to the
provisions set forth in part 1 of article 280 of title 12 and part 3 of this article 18.
Nothing in this subsection (2)(c)(XXI) exempts a person from any violation of part 4
of this article 18.
(XXII) Psilocyn;
(XXIII) Tetrahydrocannabinols;
(XXIV) Ethylamine analog of phencyclidine (Some trade or other names: N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexl) ethylamine, cyclohexamine, PCE.);
(XXV) Pyrrolidine analog of phencyclidine (Some trade or other names: 1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP.);
(XXVI) Thiophene analog of phencyclidine (Some trade or other names: 1-]1-(2-thienyl)-cyclohexyl- piperidine, 2-thienyl analog of phencyclidine, TPCP, TCP.);
(XXVII) TCPy.
(d) Any material, compound, mixture, or preparation containing any quantity
of the following substances having a depressant effect on the central nervous
system, including any salts, isomers, and salts of isomers of them that are
theoretically possible within the specific chemical designation:
(I) Mecloqualone;
(II) Methaqualone.
(e) Any material, compound, mixture, or preparation containing any quantity
of the following substances having a stimulant effect on the central nervous
system, including their salts, isomers, and salts of isomers:
(I) Repealed.
(II) Fenethylline;
(III) Methcathinone;
(IV) N-ethylamphetamine;
(V) ( + ) Cis-4-methylaminorex;
(VI) N,N-dimethylamphetamine.
(f) Any material, compound, mixture, or preparation containing any quantity
of gamma hydroxybutyrate [GHB], including its salts, isomers, and salts of isomers.
(g) Any material, compound, mixture, or preparation which is a controlled
substance analog, the chemical structure of which is substantially similar to the
chemical structure of a controlled substance listed in this subsection (2) or that was
specifically designed to produce an effect substantially similar to or greater than
the effect of a controlled substance listed in this subsection (2), all or part of which
is intended for human consumption.
(h) Any material, compound, mixture, or preparation containing any quantity
of N-benzylpiperazine (BZP), including its salts, isomers, and salts of isomers.